Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
64,111.06 +1,074.07 (+1.70%) CMC Crypto 200
1,348.55 -47.99 (-3.43%)
Telix Pharmaceuticals Ltd (T3X.BE)
| Previous close | 8.88 |
| Open | 9.09 |
| Bid | 8.62 x N/A |
| Ask | 9.35 x N/A |
| Day's range | 8.96 - 9.09 |
| 52-week range | 4.82 - 9.50 |
| Volume | |
| Avg. volume | 125 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
Australia's Telix Pharmaceuticals jumps on potential US listing
The company, however, did not disclose the number of American Depositary Shares to be issued or a timeline for the listing. No final decision has been made in respect of the Nasdaq listing, the company added. Higher interest rates caused by stubbornly elevated inflationary risks along with geopolitical tensions had dampened the sentiment for IPOs in 2023, although market participants expect a turnaround this year.
- Reuters
UPDATE 2-Australia's Telix Pharmaceuticals jumps on potential US listing
Shares of Australia's Telix Pharmaceuticals advanced on Friday after the oncology firm said that it was planning an initial public offering (IPO) in the United States and listing on the Nasdaq. The company, however, did not disclose the number of American Depositary Shares to be issued or a timeline for the listing. No final decision has been made in respect of the Nasdaq listing, the company added.
- Reuters
Australia's Telix Pharma hits record high after buying UK medical devices firm
Telix had entered an agreement to buy Lightpoint and its radio-guided surgery business SENSEI, which specialises in intra-operative detection of cancer in real time, the company said after market hours on Wednesday. Shares of Telix rose as much as 3.5% to A$12.710, their record high. The deal follows a strategic collaboration between the two companies in August 2021 to develop SENSEI for prostate cancer.
